@ch_ohlmann
Account based inGermany
About this account
- Account based in
- Germany
- Connected via
- Germany Android App
Account-level information from X, not a live location or the device used for a specific post.
Urologist specialized in Uro-Oncology and robotic Surgery, Johanniter Kliniken Bonn, Germany; Board member 'Working Group on Urologic Oncology' @auo_online
Bonn, Germany
Joined September 2015
- Tweets497
- Following211
- Followers451
- Likes85
Carsten Ohlmann retweeted
Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active systemic vs surgery will rescue many patients with aggressive micrometastatic disease. CRs for EVP=30% in M1 but should be ⬆️ in MIBC biospace.com/press-releases/…
Carsten Ohlmann retweeted
CHMP recommends durvalumab for EU approval as the first perioperative immunotherapy for MIBC.
@ASCO @myESMO @Uroweb @OncoAlert @OncBrothers @Uromigos @ProfSyedHussain @JimCatto
astrazeneca.com/media-centre…
Carsten Ohlmann retweeted
Niraparib plus Abi delays rPFS in HRR+ particularly BRCA2m mHSPC in AMPLITUDE! #ASCO25 #MedIQASCO25 HR 0.63 is clinically meaningful.
Carsten Ohlmann retweeted
Big news! The European Medicines Agency’s Committee for Medicinal Products for Human Use approved Belzutifan for advanced kidney cancer and VHL disease: actionkidneycancer.org/belzu… #KidneyCancer @ACTION4KC
Carsten Ohlmann retweeted
Big news👋. A positive R3 trial for PD-1 in NMIBC! The CREST trial evaluated sasanlimab (PD-1i)+BCG vs Standard BCG (induction and maintenance) in BCG-naïve, high-risk NMIBC.The study met its primary endpoint of EFS with ‘clinically meaningful’ results. pfizer.com/news/press-releas…
Carsten Ohlmann retweeted
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade @Cancer_Cell @OncoAlert @tompowles1 @PGrivasMDPhD
Carsten Ohlmann retweeted
Positive PFS results for the AKT inhibitor capivasertib in hormone sensitive PTEN defficent prostate cancer (with Abi and ADT). A trend towards OS (immature) described. Chemotherapy triplets are also used in high volume disease. astrazeneca.com/media-centre…
Carsten Ohlmann retweeted
Honored to present #AVENGER study results #EMUC24 - full story just submitted for publication @EUplatinum @AdvancesTherapy @Uroweb @UKSH_KI_HL @ch_ohlmann
Carsten Ohlmann retweeted
Begehbare Riesenprostata am Universitätsspital Zürich #USZ vom 04.-05. November 2024. Erleben Sie die #Prostata im #Movember hautnah. usz.ch/veranstaltung/begehba…
Carsten Ohlmann retweeted
Prior #ARANOTE #ESMO24 data @scserendipity1 @grimm_mo @myESMO @OncoAlert @Uroweb @Silke_Gillessen @APCCC_Lugano @neerajaiims @DrYukselUrun @nataliagandur @cdanicas @DGUrologie @Uroweb @declangmurphy
Platinum Priority - Editorial: Therapy Optimization in the Management of Metastatic Hormone-sensitive Prostate Cancer: Insights from the ARASENS Study by @amerseburger, Simon Chowdhury and Amit Bahl
Read the full Editorial here: buff.ly/3THWVq1
#UroSoMe #MedTwitter #EurUrol #ProstateCancer #PCa #Editorial #Urology
Carsten Ohlmann retweeted
🚨4-year follow-up of the Gothenburg MRI-targeted only vs systematic biopsy for 🚨
@NEJM
>13k patients studied
Biopsies of only MRI lesions leads to...
📉tiny.cc/otinzz
Carsten Ohlmann retweeted
🚨 Morgen startet der Deutsche Urologenkongress in Leipzig! 🩺 Freut euch auf spannende Vorträge, neueste Forschungsergebnisse und den Austausch mit Kolleg:innen aus der Urologie. #DGU24 #Urologie #Leipzig @wulfingc @DGUrologie @dgukongress @GeSRU_de @GesruAcademics @BDUrologie
Carsten Ohlmann retweeted
The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?u…
Carsten Ohlmann retweeted
Happy to share this team effort - first presented @ASCO 24 by Wolfgang Fendler. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer @ProfKHerrmann @UniklinikEssen sciencedirect.com/science/ar…
Carsten Ohlmann retweeted
CHMP gives a positive recommendation for Enfortumab Vedotin and Pembrolizumab in 1st line advanced UC. Paving the way for use in Europe. merck.com/news/merck-receive…
Change in Total Lesion PSMA (TLP) predicts survival in pts with mCRPC treated with Lu-PSMA therapy
lnkd.in/d8aCa4MH
@Prof_Ezziddin
Carsten Ohlmann retweeted
Great to have @tompowles1 at #UroTrials in Düsseldorf. Prediction: 80% less cystectomies in the next five years given recent advances in the field. So rCx only in case of local complications/bleeding in the future? @amerseburger @JimCatto @daviesbj @uretericbud
Carsten Ohlmann retweeted
Great 1. Day #urotrials meeting - kudos to @grimm_mo for setting this up 👋 @OncoAlert @APCCC_Lugano @tompowles1
Carsten Ohlmann retweeted
Positive results from the NIAGARA Phase III trial showed durvalumab with neoadjuvant chemo then cystectomy had a statistically significant and clinically meaningful improvement in EFS & OS versus chemo/cystectomy alone in muscle invasive bladder cancer astrazeneca.com/media-centre……
